Speaker Profile
M.D., Senior Vice President, Clinical Development, Clasp Tx
Biography
Dr. Harshman leads the Clinical Development efforts at Clasp Therapeutics. A medical oncologist, she brings over 15 years of experience as a practicing physician and clinical trialist first at the patient bedside and now in biotech leadership. Most recently, Lauren served as Vice President of Clinical Development at Surface Oncology, before its acquisition by Coherus Biosciences.Earlier in her career, Dr. Harshman was on faculty at Harvard Medical School and Dana-Farber Cancer Institute, where she served as Co-Director of the Kidney Cancer Center and as a Senior Physician in the Division of Oncology. She is a graduate of Cornell University and Chicago Medical School, completed her internal medicine residency at Yale, and her medical oncology fellowship at Stanford, where she later joined the faculty at Stanford Cancer Institute and Stanford School of Medicine.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Cindy Perettie, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
In-Vivo Myeloid Programming: Engineering the Innate Immune System for Solid Tumor Therapy
• Daniel Getts, Create Medicines
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
• Gudrun Stengel, Alida BioSciences
